Motley Fool Asset Management LLC Sells 2,700 Shares of Illumina, Inc. (NASDAQ:ILMN)

Key Points

• Motley Fool Asset Management LLC reduced its stake in Illumina, Inc. by 50.6%, selling 2,700 shares and holding 2,634 shares worth $209,000 at the end of the most recent quarter.
• Illumina reported earnings per share of $1.19 for the last quarter, exceeding analysts' expectations, although its revenue decreased by 4.8% year-over-year.
• The company's stock has received varied ratings from analysts, with a current average rating of "Hold" and an average price target of $124.58.

Motley Fool Asset Management LLC reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 50.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,634 shares of the life sciences company's stock after selling 2,700 shares during the quarter. Motley Fool Asset Management LLC's holdings in Illumina were worth $209,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Cerity Partners LLC grew its position in shares of Illumina by 5.0% in the 4th quarter. Cerity Partners LLC now owns 25,290 shares of the life sciences company's stock valued at $3,361,000 after buying an additional 1,214 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Illumina in the fourth quarter worth approximately $50,577,000. Townsquare Capital LLC grew its position in Illumina by 23.5% during the fourth quarter. Townsquare Capital LLC now owns 16,196 shares of the life sciences company's stock valued at $2,164,000 after buying an additional 3,087 shares during the period. Sagespring Wealth Partners LLC bought a new position in Illumina during the fourth quarter valued at $225,000. Finally, Mariner LLC grew its holdings in Illumina by 13.5% during the fourth quarter. Mariner LLC now owns 10,921 shares of the life sciences company's stock valued at $1,459,000 after purchasing an additional 1,298 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Analyst Ratings Changes

ILMN has been the topic of several recent research reports. JPMorgan Chase & Co. dropped their target price on Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Robert W. Baird increased their price objective on Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a research report on Monday, July 28th. Piper Sandler lowered their price target on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research report on Thursday, May 15th. Evercore ISI raised their price objective on Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Finally, Barclays upped their price target on Illumina from $85.00 to $90.00 and gave the company an "underweight" rating in a research report on Friday, August 1st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $124.58.

Illumina Stock Up 0.0%

NASDAQ ILMN traded up $0.02 during mid-day trading on Friday, reaching $100.11. The stock had a trading volume of 1,534,729 shares, compared to its average volume of 2,368,455. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The stock has a market cap of $15.39 billion, a PE ratio of 12.67, a price-to-earnings-growth ratio of 2.27 and a beta of 1.37. The company has a fifty day moving average price of $96.46 and a 200 day moving average price of $90.38. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the business earned $0.36 EPS. The firm's revenue for the quarter was down 4.8% on a year-over-year basis. On average, research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.